Anavex Life Sciences’ (AVXL) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research note published on Tuesday,Benzinga reports. HC Wainwright currently has a $20.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Anavex Life Sciences’ Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.33) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.15) EPS and FY2027 earnings at ($0.55) EPS.

A number of other brokerages also recently commented on AVXL. Weiss Ratings restated a “sell (d-)” rating on shares of Anavex Life Sciences in a research note on Monday, December 29th. Jones Trading downgraded Anavex Life Sciences from a “buy” rating to a “hold” rating in a report on Friday, October 24th. Finally, D. Boral Capital restated a “buy” rating and set a $24.00 price objective on shares of Anavex Life Sciences in a research note on Monday. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Anavex Life Sciences presently has a consensus rating of “Hold” and a consensus target price of $22.00.

Anavex Life Sciences Price Performance

AVXL stock opened at $3.92 on Tuesday. The firm has a market cap of $363.27 million, a price-to-earnings ratio of -8.52 and a beta of 1.21. Anavex Life Sciences has a 1-year low of $2.86 and a 1-year high of $13.99. The firm has a fifty day moving average price of $4.27 and a two-hundred day moving average price of $6.92.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings results on Monday, February 9th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04. As a group, analysts expect that Anavex Life Sciences will post -0.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of AVXL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Anavex Life Sciences by 10.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,525 shares of the biotechnology company’s stock worth $434,000 after purchasing an additional 4,869 shares during the period. Stratos Wealth Partners LTD. bought a new stake in shares of Anavex Life Sciences during the 2nd quarter worth about $245,000. 180 Wealth Advisors LLC lifted its stake in shares of Anavex Life Sciences by 213.4% in the 2nd quarter. 180 Wealth Advisors LLC now owns 44,050 shares of the biotechnology company’s stock worth $406,000 after acquiring an additional 29,995 shares during the period. Atria Investments Inc boosted its holdings in shares of Anavex Life Sciences by 18.2% in the second quarter. Atria Investments Inc now owns 22,110 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 3,406 shares in the last quarter. Finally, Kovack Advisors Inc. bought a new position in shares of Anavex Life Sciences in the second quarter valued at approximately $93,000. Institutional investors own 31.55% of the company’s stock.

Trending Headlines about Anavex Life Sciences

Here are the key news stories impacting Anavex Life Sciences this week:

• Positive Sentiment: HC Wainwright raised multiple 2026 EPS estimates (Q2, Q3, Q4 and FY2026) and now models FY2026 at a smaller loss, while reiterating a “Buy” rating and a $20.00 price target — a material positive for sentiment and valuation expectations. Read More.
• Positive Sentiment: Zacks upgraded Anavex to a Zacks Rank #2 (Buy), signaling growing optimism about its earnings prospects and placing additional buy‑side attention on the ticker. Read More.
• Positive Sentiment: HC Wainwright also published multi‑quarter and FY2027 EPS projections (new estimates for Q1–Q4 2027 and FY2027) alongside its coverage, reinforcing analyst engagement and a bullish $20 target. Read More.
• Neutral Sentiment: Analyst/sector comparison pieces note how AVXL is performing vs. medical peers year‑to‑date — useful for relative performance context but not an immediate catalyst. Read More.
• Neutral Sentiment: Short‑interest data reported for early February shows 0 shares and anomalous “NaN” increases — this appears to be a reporting/data issue rather than a real build in short pressure, so it’s not currently informative for direction. (Internal short‑interest entries 2/11–2/12)

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.